1. Home
  2. MPU vs PRPO Comparison

MPU vs PRPO Comparison

Compare MPU & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPU

Mega Matrix Corp.

HOLD

Current Price

$0.73

Market Cap

44.8M

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$29.49

Market Cap

44.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPU
PRPO
Founded
1989
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
44.4M
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
MPU
PRPO
Price
$0.73
$29.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
47.1K
12.0K
Earning Date
03-09-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.15
EPS
N/A
N/A
Revenue
N/A
$24,049,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.77
52 Week Low
$0.57
$5.21
52 Week High
$4.44
$29.53

Technical Indicators

Market Signals
Indicator
MPU
PRPO
Relative Strength Index (RSI) 43.58 59.48
Support Level $0.72 $22.96
Resistance Level $0.81 $28.76
Average True Range (ATR) 0.04 1.73
MACD -0.00 0.18
Stochastic Oscillator 53.54 82.12

Price Performance

Historical Comparison
MPU
PRPO

About MPU Mega Matrix Corp.

Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: